Estival, AnnaSanz, CarolinaRamirez, Jose-LuisVelarde, Jose MariaDomenech, MartaCarrato, Cristinade Las Peñas, RamónGil-Gil, MiguelSepúlveda, JuanArmengol, RoserCardiel, IsaacBerrocal, AlfonsoLuque, RaquelHerrero, AnaBalana, Carmen2025-01-072025-01-072019-07-31https://hdl.handle.net/10668/26276Circulating biomarkers in blood may provide an interesting alternative to risky tissue biopsies in the diagnosis and follow-up of glioblastoma patients. We have assessed MGMT methylation status in blood and tissue samples from unresected glioblastoma patients who had been included in the randomized GENOM-009 trial. Paired blood and tissue samples were assessed by methylation-specific PCR (MSP) and pyrosequencing (PYR). After establishing the minimum PYR cut-off that could yield a significant difference in overall survival, we assessed the sensitivity, specificity, positive predictive value and negative predictive value (NPV) of the analyses. Methylation could be detected in cfDNA by both MSP and PYR but with low concordance with results in tissue. Sensitivity was low for both methods (31% and 38%, respectively), while specificity was higher for MSP in blood than for PYR in plasma (96% vs 76%) and NPV was similar (56 vs 57%). Concordance of results in tissue by MSP and PYR was 84.3% (P enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/BiomarkersBrain NeoplasmsDNA MethylationDNA Modification MethylasesDNA Repair EnzymesFemaleGlioblastomaHumansMaleMiddle AgedPolymerase Chain ReactionSensitivity and SpecificityTumor Suppressor Proteinsresearch article31366977open access10.1038/s41598-019-47642-22045-2322PMC6668570https://www.nature.com/articles/s41598-019-47642-2.pdfhttps://pmc.ncbi.nlm.nih.gov/articles/PMC6668570/pdf